Marburg I Polymorphism of Factor VII–Activating Protease A Prominent Risk Predictor of Carotid Stenosis

Background— Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease “factor seven–activating protease” (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I pol...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 107; no. 5; pp. 667 - 670
Main Authors Willeit, Johann, Kiechl, Stefan, Weimer, Thomas, Mair, Artur, Santer, Peter, Wiedermann, Christian J., Roemisch, Juergen
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 11.02.2003
American Heart Association, Inc
Subjects
Online AccessGet full text
ISSN0009-7322
1524-4539
1524-4539
DOI10.1161/01.CIR.0000055189.18831.B1

Cover

Abstract Background— Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease “factor seven–activating protease” (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis. Methods and Results— This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes. Conclusions— In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.
AbstractList Background— Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease “factor seven–activating protease” (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis. Methods and Results— This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes. Conclusions— In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.
Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis.BACKGROUNDAtherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis.This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes.METHODS AND RESULTSThis analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes.In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.CONCLUSIONSIn concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.
Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis. This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes. In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.
BACKGROUND: Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine protease "factor seven-activating protease" (FSAP) was recognized as a potent activator of prourokinase in vitro. The Marburg I polymorphism of FSAP impairs this potential and may thus facilitate arterial thrombosis. METHODS AND RESULTS: This analysis of the Bruneck Study involved 810 men and women aged 40 to 79 years. The ultrasound-based atherosclerosis progression model (5-year follow-up) permits differentiation between early atherogenesis and the advanced stenotic stages of carotid artery disease. The FSAP Marburg I polymorphism was found in 37 subjects (carriage rate 4.4%). Individuals with this genetic variant showed a prominently reduced in vitro capacity to activate prourokinase. No relation was found to exist between the Marburg I polymorphism and early atherogenesis. In contrast, it emerged as a strong and independent risk predictor of incident/progressive carotid stenosis (multivariate odds ratio [95%CI], 6.6 [1.6 to 27.7]). This finding equally applied to subjects with and without co-segregation of the Marburg II polymorphism. The risk profile of advanced atherogenesis further includes cigarette smoking, high lipoprotein(a), the factor V Leiden mutation, low antithrombin III, high fibrinogen, and diabetes. CONCLUSIONS: In concert with other genetic and acquired conditions known to interfere with coagulation or fibrinolysis, the Marburg I polymorphism of FSAP, which attenuates its capacity to activate prourokinase, is a significant risk predictor for the evolution and progression of carotid stenosis.
Author Kiechl, Stefan
Mair, Artur
Weimer, Thomas
Santer, Peter
Wiedermann, Christian J.
Roemisch, Juergen
Willeit, Johann
Author_xml – sequence: 1
  givenname: Johann
  surname: Willeit
  fullname: Willeit, Johann
  organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany
– sequence: 2
  givenname: Stefan
  surname: Kiechl
  fullname: Kiechl, Stefan
  organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany
– sequence: 3
  givenname: Thomas
  surname: Weimer
  fullname: Weimer, Thomas
  organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany
– sequence: 4
  givenname: Artur
  surname: Mair
  fullname: Mair, Artur
  organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany
– sequence: 5
  givenname: Peter
  surname: Santer
  fullname: Santer, Peter
  organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany
– sequence: 6
  givenname: Christian J.
  surname: Wiedermann
  fullname: Wiedermann, Christian J.
  organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany
– sequence: 7
  givenname: Juergen
  surname: Roemisch
  fullname: Roemisch, Juergen
  organization: From the Departments of Neurology (J.M., S.K., A.M.) and Internal Medicine (C.J.W.), University Clinics, Innsbruck, Austria; Laboratory Medicine (P.S.), Bruneck Hospital, Bruneck, Italy; and Aventis Behring GmbH (T.W., J.R.), Research, Marburg, Germany
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14544080$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/12578864$$D View this record in MEDLINE/PubMed
BookMark eNqN0c1O3DAQB3CrApVlyyugCIneEjz-DidgVdpIIFDVcrUcrwNBSbzYSSVufYe-YZ-k3rJoJU74Yln-zWg0_320M_jBIXQEuAAQcIKhWFTfC7w-nIMqC1CKQnEBH9AMOGE547TcQbP0X-aSErKH9mN8TE9BJf-I9oBwqZRgM3R6bUI9hfusym5999z7sHpoY5_5Jrs0dvQhu6uqv7__nNux_WXGdrjPboMfnYnuE9ptTBfdweaeo5-XX34svuVXN1-rxflVbhnQMa9rTEGWDQEmhGRE0MaShi9pyeSyFEsmcMmsw2tNVU2VJLI2SpSOc-YEoXP0-aXvKvinycVR9220ruvM4PwUtaQYS5L6ztHRG_jopzCk2TQBIjlWQiV0uEFT3bulXoW2N-FZv64kgeMNMNGarglmsG3cOsYZwwond_ribPAxBtdsCdbrnDQGnXLS25z0_5z0BaTiszfFth3Tev0wBtN272nxD4T2lmU
CODEN CIRCAZ
CitedBy_id crossref_primary_10_1096_fj_202200828R
crossref_primary_10_1191_1358863x05vm609oa
crossref_primary_10_1160_TH17_02_0081
crossref_primary_10_2491_jjsth_21_3
crossref_primary_10_1161_JAHA_120_016445
crossref_primary_10_1007_s11010_019_03501_2
crossref_primary_10_1016_j_thromres_2012_07_023
crossref_primary_10_1038_s41392_021_00802_1
crossref_primary_10_5482_ha_1159
crossref_primary_10_1111_jth_13417
crossref_primary_10_1056_NEJMc1511631
crossref_primary_10_1016_j_jvs_2006_06_016
crossref_primary_10_1016_j_thromres_2010_03_003
crossref_primary_10_1038_s41598_019_55531_x
crossref_primary_10_1074_jbc_M112_433029
crossref_primary_10_1515_CCLM_2011_199
crossref_primary_10_1096_fj_03_0898fje
crossref_primary_10_1097_MBC_0000000000000640
crossref_primary_10_1378_chest_126_3_suppl_265S
crossref_primary_10_1016_j_atherosclerosis_2007_03_042
crossref_primary_10_1093_hmg_ddab124
crossref_primary_10_1182_blood_2004_08_3328
crossref_primary_10_1042_BJ20070166
crossref_primary_10_5551_jat_9589
crossref_primary_10_1016_j_atherosclerosis_2017_08_029
crossref_primary_10_1111_j_1538_7836_2012_04692_x
crossref_primary_10_1074_jbc_M610748200
crossref_primary_10_1016_j_thromres_2019_08_016
crossref_primary_10_1160_TH14_06_0519
crossref_primary_10_3109_13697131003597027
crossref_primary_10_1042_BJ20041021
crossref_primary_10_1002_cbic_201900705
crossref_primary_10_1002_prca_201300078
crossref_primary_10_1111_j_1538_7836_2009_03641_x
crossref_primary_10_1111_j_1742_4658_2009_07183_x
crossref_primary_10_1016_j_bbadis_2018_07_030
crossref_primary_10_1016_j_bbrc_2011_05_030
crossref_primary_10_1111_j_1538_7836_2009_03718_x
crossref_primary_10_3390_cells8111396
crossref_primary_10_1016_j_thromres_2008_02_002
crossref_primary_10_1007_s11239_013_0921_0
crossref_primary_10_3389_fneur_2022_1076898
crossref_primary_10_3389_fneur_2023_1174425
crossref_primary_10_4049_jimmunol_1103029
crossref_primary_10_1021_acschembio_2c00538
crossref_primary_10_1084_jem_20052546
crossref_primary_10_1016_j_ejogrb_2012_10_035
crossref_primary_10_1515_CCLM_2008_218
crossref_primary_10_1042_BJ20051563
crossref_primary_10_1016_j_thromres_2012_02_009
crossref_primary_10_1182_blood_2005_02_0576
crossref_primary_10_1016_j_febslet_2009_05_012
crossref_primary_10_1016_j_jhep_2012_09_007
crossref_primary_10_1111_ejn_12830
crossref_primary_10_1177_0268355519881604
crossref_primary_10_1515_CCLM_2010_334
crossref_primary_10_4061_2011_424759
crossref_primary_10_5551_jat_53074
crossref_primary_10_1016_j_molimm_2021_11_019
crossref_primary_10_1111_jth_14258
crossref_primary_10_3390_ijms232213706
crossref_primary_10_1016_j_atherosclerosis_2013_08_007
crossref_primary_10_1016_j_thromres_2020_02_010
crossref_primary_10_1080_1354750X_2018_1434681
crossref_primary_10_1177_1747493016641949
crossref_primary_10_1210_jc_2015_3928
crossref_primary_10_1002_hep_22707
crossref_primary_10_1016_j_thromres_2022_09_027
crossref_primary_10_1042_BJ20061630
crossref_primary_10_5482_ha_1187
crossref_primary_10_1016_j_intimp_2007_10_012
Cites_doi 10.1093/oxfordjournals.jbchem.a021861
10.1182/blood.V96.5.1820
10.1161/atvb.19.6.1491
10.1097/00001721-200201000-00001
10.1093/oxfordjournals.jbchem.a021362
10.1055/s-0037-1614949
10.1161/atvb.20.2.529
10.1515/BC.2002.121
10.1161/atvb.19.6.1484
ContentType Journal Article
Copyright 2003 INIST-CNRS
Copyright American Heart Association, Inc. Feb 11 2003
Copyright_xml – notice: 2003 INIST-CNRS
– notice: Copyright American Heart Association, Inc. Feb 11 2003
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
U9A
7X8
DOI 10.1161/01.CIR.0000055189.18831.B1
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Career and Technical Education (Alumni Edition)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 670
ExternalDocumentID 289936411
12578864
14544080
10_1161_01_CIR_0000055189_18831_B1
Genre Journal Article
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
0ZK
18M
1J1
29B
2FS
2WC
354
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAAV
AAAXR
AAFWJ
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AARTV
AASOK
AAUEB
AAWTL
AAXQO
AAYXX
ABBUW
ABDIG
ABJNI
ABOCM
ABPMR
ABPXF
ABQRW
ABXVJ
ABZAD
ACCJW
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACILI
ACOAL
ACRKK
ACWDW
ACWRI
ACXNZ
ACZKN
ADBBV
ADCYY
ADFPA
ADGGA
ADHPY
ADKSD
ADNKB
AE3
AE6
AEETU
AENEX
AFCHL
AFDTB
AFEXH
AFFNX
AFNMH
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
ALKUP
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMNEI
ASPBG
AVWKF
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BS7
BYPQX
C1A
C45
CITATION
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FEDTE
FL-
FW0
GX1
H0~
H13
HVGLF
HZ~
H~9
IKREB
IKYAY
IN~
J5H
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
M18
N4W
N9A
NEJ
N~7
N~B
N~M
O9-
OAG
OAH
OBH
OCB
OCUKA
ODA
ODMTH
OGEVE
OHH
OHT
OHYEH
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
R58
RAH
RLZ
S4R
S4S
T8P
TEORI
TR2
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WHG
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YOC
YSK
YYM
YYP
YZZ
ZFV
ZGI
ZXP
ZY1
ZZMQN
~H1
1CY
41~
AAEJM
AAQKA
AASCR
AASXQ
ABASU
ABVCZ
ABXYN
ABZZY
ACLDA
ACXJB
AEBDS
AFBFQ
AFMBP
AFSOK
AHQVU
AJJEV
AKCTQ
AKULP
ALMTX
AMKUR
AOHHW
AOQMC
EEVPB
EJD
ERAAH
GNXGY
GQDEL
HLJTE
IPNFZ
IQODW
MVM
P-K
RIG
TSPGW
YQJ
YXB
AAYOK
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OJAPA
OLW
PKN
RHF
K9.
NAPCQ
U9A
7X8
ID FETCH-LOGICAL-c413t-bb03179f2146674263fc2f5d3947d96d46094ce0c41338b38727ba869e554e623
ISSN 0009-7322
1524-4539
IngestDate Mon Sep 08 11:51:57 EDT 2025
Fri Jul 25 03:39:20 EDT 2025
Wed Feb 19 02:32:06 EST 2025
Mon Jul 21 09:17:22 EDT 2025
Thu Apr 24 23:08:50 EDT 2025
Wed Oct 01 02:48:26 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Human
Nervous system diseases
risk factors
Enzyme
Stenosis
Cardiovascular disease
Genetic determinism
Thrombosis
Cerebral disorder
Factor VII
Arterial disease
Vascular disease
Peptidases
Carotid
Central nervous system disease
Atherosclerosis
Risk factor
thrombolysis
Hydrolases
Cerebrovascular disease
Polymorphism
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c413t-bb03179f2146674263fc2f5d3947d96d46094ce0c41338b38727ba869e554e623
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 12578864
PQID 212750868
PQPubID 24119
PageCount 4
ParticipantIDs proquest_miscellaneous_73007226
proquest_journals_212750868
pubmed_primary_12578864
pascalfrancis_primary_14544080
crossref_primary_10_1161_01_CIR_0000055189_18831_B1
crossref_citationtrail_10_1161_01_CIR_0000055189_18831_B1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2003-02-11
PublicationDateYYYYMMDD 2003-02-11
PublicationDate_xml – month: 02
  year: 2003
  text: 2003-02-11
  day: 11
PublicationDecade 2000
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
– name: Baltimore
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 2003
Publisher Lippincott Williams & Wilkins
American Heart Association, Inc
Publisher_xml – name: Lippincott Williams & Wilkins
– name: American Heart Association, Inc
References e_1_3_2_9_2
e_1_3_2_8_2
e_1_3_2_7_2
e_1_3_2_1_2
(e_1_3_2_6_2) 2001; 12
e_1_3_2_10_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_2_2
(e_1_3_2_3_2) 1999; 76
12578860 - Circulation. 2003 Feb 11;107(5):654-5
References_xml – ident: e_1_3_2_2_2
  doi: 10.1093/oxfordjournals.jbchem.a021861
– ident: e_1_3_2_12_2
  doi: 10.1182/blood.V96.5.1820
– volume: 12
  start-page: 376
  year: 2001
  ident: e_1_3_2_6_2
  publication-title: Blood Coag Fibrinol
– ident: e_1_3_2_8_2
  doi: 10.1161/atvb.19.6.1491
– ident: e_1_3_2_5_2
  doi: 10.1097/00001721-200201000-00001
– ident: e_1_3_2_10_2
– ident: e_1_3_2_1_2
  doi: 10.1093/oxfordjournals.jbchem.a021362
– ident: e_1_3_2_11_2
  doi: 10.1055/s-0037-1614949
– volume: 76
  start-page: 292
  year: 1999
  ident: e_1_3_2_3_2
  publication-title: Haemostasis
– ident: e_1_3_2_9_2
  doi: 10.1161/atvb.20.2.529
– ident: e_1_3_2_4_2
  doi: 10.1515/BC.2002.121
– ident: e_1_3_2_7_2
  doi: 10.1161/atvb.19.6.1484
– reference: 12578860 - Circulation. 2003 Feb 11;107(5):654-5
SSID ssj0006375
Score 2.064461
Snippet Background— Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the...
Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the plasmatic serine...
BACKGROUND: Atherothrombosis is a main pathomechanism in the evolution of vessel stenosis and is counteracted by endogenous fibrinolysis. Recently, the...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 667
SubjectTerms Adult
Aged
Biological and medical sciences
Carotid Stenosis - diagnostic imaging
Carotid Stenosis - epidemiology
Carotid Stenosis - genetics
Cohort Studies
Disease Progression
DNA Mutational Analysis
Enzyme Activation - genetics
Female
Follow-Up Studies
Gene Frequency
Heterozygote
Homozygote
Humans
Italy - epidemiology
Male
Medical sciences
Middle Aged
Neurology
Odds Ratio
Polymorphism, Genetic
Predictive Value of Tests
Prospective Studies
Risk Assessment
Risk Factors
Serine Endopeptidases - genetics
Ultrasonography
Urokinase-Type Plasminogen Activator - metabolism
Vascular diseases and vascular malformations of the nervous system
Subtitle A Prominent Risk Predictor of Carotid Stenosis
Title Marburg I Polymorphism of Factor VII–Activating Protease
URI https://www.ncbi.nlm.nih.gov/pubmed/12578864
https://www.proquest.com/docview/212750868
https://www.proquest.com/docview/73007226
Volume 107
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1524-4539
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0006375
  issn: 0009-7322
  databaseCode: KQ8
  dateStart: 19500101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1524-4539
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0006375
  issn: 0009-7322
  databaseCode: DIK
  dateStart: 19500101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1524-4539
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0006375
  issn: 0009-7322
  databaseCode: GX1
  dateStart: 19500101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBASQrDBKIPhB7SXKqX5chLeRtm0wDok1ELfLCdxINKWlDZ9gL-CP5m72PkodGLwEjVuLol8v5zPvvP9CHlpOW4iokAaOJobcMIMUHNkgDNngX-aCLPiIphcsLOZ827uznu9n52spXUZDeMfW_eV_I9WoQ30irtk_0GzzU2hAX6DfuEIGobjjXQ8EdgnXwYhci3AJB76DDkvwP9TNDqDT2FoGLh1ARdeq23nRYnxGLXFGc6uwMnMS5Vgvlhi0AbFMNVcwKVZMgAQ5MUqW3Wd2HG2jDXr1zYyn87iAq7myKzUOb8i74T8Zfz1UqeZpS1CP8tM07l0MpeqBfNMsW4vYYjcWKnA-LChLak2rpYDcFDFi4ZyS1ttkRURroae27GvTHF3_Gn3mVntZRjG2VKVpMRKc8HQ9H3bHEZmO9rVEf6LD_x0dn7Opyfz6dHim4E8ZBiv16Qst8hty2MMOTHehu-bsZ3ZVenm5q11GVt4_KvrH77h8txbiBV8famiTbl-XlP5N9MH5L6emNBjhbKHpCfzXbJ3nIuyuPpOj2iVKlzFYHbJnYnOyNgjmcYgDWkXg7RIqcIg_Q2DtMbgaypog0CKCKQNAlFcI5DWCHxEZqcn0_GZoek7jBg8o9KIIhgwvCBF6njmITFAGlupm9iB4yUBSxw2CpxYjvBq249sH1zpSPgskODiSnDLH5OdvMjlE0JjsHfCDvxY-uCOBiCXCitynXjkS8uJvD4J6h7msa5tjxQrl7ya4zKTj0w-Dj_yVju80g5_Y_aJ3cguVIWXG0kdbiiyFXVcJHEf9clBrVmuTcaKKzoFn_l98qL5F-w5BulELov1iiN_hAd2sk_2FRzaO-Po6jPn6V9lD8jd9vt7RnbK5Vo-B9-5jA4rOP8CfX--nA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Marburg+I+polymorphism+of+factor+VII--activating+protease%3A+a+prominent+risk+predictor+of+carotid+stenosis&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Willeit%2C+Johann&rft.au=Kiechl%2C+Stefan&rft.au=Weimer%2C+Thomas&rft.au=Mair%2C+Artur&rft.date=2003-02-11&rft.issn=1524-4539&rft.eissn=1524-4539&rft.volume=107&rft.issue=5&rft.spage=667&rft_id=info:doi/10.1161%2F01.cir.0000055189.18831.b1&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon